Sterling Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Sterling Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$42.4K	Buy	2,061 +399	+24%	+$8.52K	﹤0.01%	1841
2026 Q2	$30.5K	Buy	1,662 +676	+69%	+$10.9K	﹤0.01%	1711
2026 Q1	$19.3K	Sell	986 -384	-28%	-$11.4K	﹤0.01%	2047
2025 Q4	$42.6K	Buy	1,370 +230	+20%	+$6.31K	﹤0.01%	1855
2025 Q3	$24.6K	Buy	1,140 +623	+121%	+$11.2K	﹤0.01%	2043
2025 Q2	$7.23K	Buy	517 +121	+31%	+$1.64K	﹤0.01%	2313
2025 Q1	$5.34K	Sell	396 -271	-41%	-$4.62K	﹤0.01%	2139
2024 Q4	$12.8K	Buy	667 +567	+567%	+$12.3K	﹤0.01%	2053
2024 Q3	$2.28K	Buy	+100	New	+$1.64K	﹤0.01%	2128

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Sterling Capital Management's VRDN Position: Q3 2026 in Review

Sterling Capital Management increased its Viridian Therapeutics (VRDN) stake by 24% in Q3 2026, buying an estimated $8.52K and bringing the position to 2,061 shares worth $42.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1841.

Sterling Capital Management first reported a position in VRDN in Q3 2024 and has held it in 9 quarters since. The position peaked at $42.6K in Q4 2025. 94 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

Sterling Capital Management held 2,061 shares of Viridian Therapeutics worth $42.4K as of Q3 2026.
Sterling Capital Management bought 399 Viridian Therapeutics shares in Q3 2026, an estimated $8.52K.
Viridian Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #1841 holding.
Sterling Capital Management first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 9 quarters since.
Sterling Capital Management's Viridian Therapeutics position peaked at $42.6K in Q4 2025.
94 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.